Skip to main content
TipRanks
Go Ultimate75% OFF

Codexis (4QK) Stock Price & Analysis

0 Followers

4QK Stock Chart & Stats

€0.94-€0.09(-8.62%)
At close: 5:30 PM GMT+1
€1€1.2€1.4Aug 21Sep 23Oct 7Nov 3Nov 16
Day’s Range
EUR 0.94 - EUR 1.04
52-Week Range
EUR 0.82 - EUR 2.45
Previous Close
EUR 1.03
Volume
N/A
Average Volume (3M)
120
Market Cap
EUR 105.69M
Enterprise Value
EUR 148.70M
Total Cash (Recent Filing)
EUR 72.66M
Total Debt (Recent Filing)
EUR 72.27M
Price to Earnings (P/E)
―
Beta
0.93
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Product Growth

Strong recent revenue and product-sales growth indicates improving commercial traction across Codexis’s pharma biocatalysis business. Continued adoption of proprietary enzymes can expand recurring supply opportunities, strengthen customer relationships, and support a more durable revenue base.

ECO Synthesis Platform Progress

Progress in scale, cycle time, and product purity strengthens the technical case for ECO Synthesis as a commercially viable platform. These improvements can support larger customer programs, improve process economics, and increase the likelihood of adoption in future oligonucleotide manufacturing.

Improving Gross Margins

High and improving product gross margins demonstrate attractive economics for Codexis’s enzyme offerings and suggest that commercial growth need not require proportionate cost increases. Sustained margins could provide greater operating leverage as revenue expands and expenses scale more efficiently.

Bears Say

Persistent Net Losses

Codexis remains loss-making even after a substantial year-over-year improvement, showing that strong gross margins have not yet translated into sustainable earnings. Continued losses could constrain reinvestment capacity and leave the business dependent on operating improvements or external financing.

Elevated Leverage

The sharp increase in leverage reduces financial flexibility while Codexis is still reporting losses and negative cash flow. Higher debt obligations can absorb future cash resources, restrict capital allocation, and increase the company’s exposure to financing and covenant requirements.

Scale-Up And Commercial Timing Risk

Codexis has demonstrated meaningful technical progress, but larger-scale readiness and commercial deployment remain unfinished. Delays in process optimization, regulatory work, or customer negotiations could postpone revenue conversion and extend the period before platform investments generate significant returns.

Codexis News

4QK FAQ

What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was €0.82 and its highest was €2.45 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is €105.69M.
When is Codexis’s upcoming earnings report date?
Codexis’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 100 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on Nov 12, 2026. The company reported -€0.073 earnings per share for the quarter, beating the consensus estimate of -€0.087 by €0.015.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.07.
How many shares outstanding does Codexis have?
Codexis has 109,597,530 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -€0.073 in its last earnings report, beating expectations of -€0.087. Following the earnings report the stock price went up 23.27%.
Which hedge fund is a major shareholder of Codexis?
Hedge funds hold Codexis shares: the largest hedge-fund position in Codexis is 1,310,034,199 shares, and hedge funds increased their holdings by 12.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology